Healthcare Realty Trust (HR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to elect six directors, ratify Deloitte & Touche LLP as auditor, and hold a non-binding advisory vote on executive compensation.
Shareholders of record as of March 26, 2026, are entitled to vote; 346,534,039 shares outstanding.
Proxy materials are distributed electronically, with options for mail or email upon request.
Voting matters and shareholder proposals
Proposals include election of six directors, auditor ratification, and a say-on-pay vote.
Board recommends voting FOR all nominees and proposals.
Shareholders can submit proposals or director nominations for the 2027 meeting between Nov 8 and Dec 8, 2026.
Board of directors and corporate governance
Board consists of seven members; six nominated for re-election, with diverse backgrounds in real estate, finance, and executive leadership.
Chair and CEO roles are separated; majority of directors are independent.
Committees: Audit, Nominating and Corporate Governance, Compensation and Human Capital—all comprised of independent directors.
Proxy access allows qualifying shareholders to nominate directors.
Board held 14 meetings in 2025; all directors attended at least 75%.
Latest events from Healthcare Realty Trust
- Record leasing and 6.9% NOI growth drove raised guidance and $100M in share repurchases.HR
Q1 20265 May 2026 - Strong NOI growth, high occupancy, and disciplined capital allocation drive sector leadership.HR
Investor presentation30 Apr 2026 - Director elections, auditor ratification, and say-on-pay headline the 2026 annual meeting.HR
Proxy filing7 Apr 2026 - Strong leasing, $1.2B asset sales, and improved leverage drive positive 2025 and 2026 outlook.HR
Q4 202513 Feb 2026 - Q2 net loss on impairments, but strong leasing, asset sales, and FFO guidance affirmed.HR
Q2 20242 Feb 2026 - Normalized FFO per share rose 1.2% as leasing, asset sales, and share buybacks drove activity.HR
Q3 202417 Jan 2026 - Record leasing, robust FFO growth, and deleveraging highlight 2024 performance.HR
Q4 202429 Dec 2025 - Normalized FFO per share was $0.39 in Q1 2025, with improved net loss and strong leasing.HR
Q1 202527 Dec 2025 - Board recommends approval of all proposals, with strong focus on pay-for-performance and ESG.HR
Proxy Filing1 Dec 2025